卵巢癌的一线维持治疗时机和药物选择？

参考文献

[1]孔北华,刘继红,黄鹤,等.卵巢癌PARP抑制剂临床应用指南（2022版）[J].现代妇产科进展,2022,31(08):561-572.

[2] 卢淮武,徐冬冬,赵喜博,等.《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J].中国实用妇科与产科志,2024,40(02):187-197.DOI:10.19538/j.fk2024020113.

[3] 王文翔,段远琼,尹如铁.PARP抑制剂在卵巢癌中的应用美国临床肿瘤学会指南快速更新推荐解读[J].实用妇产科杂志,2023,39(01):34-37.

[4]2023年CSCO卵巢癌诊疗指南

[5]Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681-692.

[6]Lingying Wu, Ning Li, Jing Wang, et al. Fuzuloparib as maintenance therapy in patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial. 2024 SGO. Poster Number111.

[7] Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I,et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. PMID: 39284381.